Business Wire Industry News

Friday, October 16, 2026

EmeraNova™ Expands Access to Wound Imaging, Supporting Clinical Diagnostic Capabilities

PHOENIX--(BUSINESS WIRE)--Following yesterday’s milestone launch announcement, EmeraNova™, the new corporate identity of BioLab Holdings and a medical technology company building an advanced tissue restoration platform, has announced a collaboration that will expand its portfolio into an entirely new category and allow it to enter additional care settings. Technology leader Kent Imaging is teaming up with EmeraNova to bring advanced wound imaging to wound care clinics, surgical centers, hospita

Thursday, October 15, 2026

Bioscience Association Manitoba Welcomes New Board Members and Executive Members at Annual General Meeting

WINNIPEG, Manitoba--(BUSINESS WIRE)--The Bioscience Association Manitoba (BAM) is pleased to announce the appointment of new members to its Board of Directors and Executive Board, following the organization’s Annual General Meeting held on October 15, 2026. The new BAM Board brings together leaders from across Manitoba’s bioscience community, representing a range of expertise, organizations, and sectors. Together, they will help guide BAM’s work to strengthen Manitoba’s bioscience ecosystem, su

Thursday, October 15, 2026

BioLab Holdings Launches EmeraNova™ to Advance the Future of Tissue Restoration

PHOENIX--(BUSINESS WIRE)--BioLab Holdings announced today a new, larger mission with the launch of EmeraNova™, a new corporate identity that reflects a broader ambition to advance tissue restoration across specialties, healing phases, and care settings. The launch marks the company’s efforts to build a global platform focused on identifying promising technologies and accelerating their path into clinical practice. EmeraNova represents a vision to pursue emerging (Emer) and new (Nova) technologi

Thursday, October 15, 2026

BioTalent Canada Announces Recipients of Its Annual I.D.E.A.L. Scholarship™

OTTAWA, Ontario--(BUSINESS WIRE)-- #bioeconomy--BioTalent Canada today released the names of the three recipients of the I.D.E.A.L. (Inclusion, Diversity, Equite and Accessibility Leadership) Scholarship™. Now in its third year, the scholarship recognizes individuals entering a bioscience-related study who have championed IDEAL in their daily lives. Each recipient will receive $10,000 to support their post-secondary studies and advance a future in which talent, lived experience and bold ideas shape Canada’s

Thursday, October 15, 2026

VectorBuilder to Present at the ASHG 2026 Annual Meeting

CHICAGO--(BUSINESS WIRE)-- #BioTechNews--VectorBuilder today announced that it will present and exhibit at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montréal, Canada, and that Dr. Morgan Dwyer will present during the meeting. Dwyer will present “Development of a Compact Bidirectional Promoter for Coordinated Multi-Gene Expression” as part of the Translational and Technological Advances in Genetic Therapies session on Saturday, October 24 at 8:45 a.m. The

Thursday, October 15, 2026

Beren Therapeutics Presents New Adrabetadex Data Showing Preservation of Neurological Function for More Than 10 Years in Children with Infantile-Onset NPC

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C., a leader in cholesterol-trafficking biology and novel cyclodextrin-based therapeutics, today announced new long-term data demonstrating neurological function was preserved for more than 10 years following initiation of treatment with adrabetadex, an investigational cyclodextrin-based medicine under review by the U.S. Food and Drug Administration (FDA) for infantile-onset Niemann-Pick disease, type C (I-NPC). A case study contain

Thursday, October 15, 2026

Sunnybrook Announces the Marg Gillespie Precision Oncology Centre to Advance Personalized Cancer Care

TORONTO--(BUSINESS WIRE)--Sunnybrook Health Sciences Centre is proud to announce plans to build the Marg Gillespie Precision Oncology Centre, made possible by $29 million in philanthropic support from Sunnybrook’s donor community, including a lead gift from the Gillespie family. Expected to open in 2029, the 7,800-square-foot space located within Sunnybrook’s Odette Cancer Centre, will increase Sunnybrook’s capacity to lead cancer research and support a broader range of clinical trials. “Every

Wednesday, October 14, 2026

SOLVE FSHD Portfolio Company Altay Therapeutics Closes $37 Million Series A Financing to Advance DX5057 for FSHD

VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD, a venture-philanthropy organization dedicated to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today celebrated the closing of a US$37 million Series A financing by portfolio company Altay Therapeutics, Inc. The financing was co-led by Sound Bioventures and HealthCap, with participation from Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital and Global BioAccess Fund. Altay intends to use the pr

Tuesday, October 13, 2026

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 45,940 common shares of the Company (the "Options") with effective grant dates of October 13, 2026

Tuesday, October 13, 2026

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition" or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent Application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026, as U.S. Patent Applicatio

Tuesday, October 13, 2026

enGene to Host KOL Webinar on October 15, 2026

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, no

Friday, October 9, 2026

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy. ME Therapeutics will continue developing the CD

Thursday, October 8, 2026

Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed to characterize disease progression in pediatric participants with severe, non-attenua

Thursday, October 8, 2026

TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, 2026, in Toronto, Canada. The presentations include a late-breaking oral presentation highlighting initial results from a Phase 1 study evaluating azer-cel in patients with primary progressive multiple sclerosis (PPMS), as well as several presentations highlighting BRIUMVI®

Wednesday, October 7, 2026

Medisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical Compounding

MONTREAL--(BUSINESS WIRE)-- #APIs--Medisca and EUROAPI have formed a strategic partnership focused on expanding API access for pharmaceutical compounding, creating differentiated access in North America and establishing a broader framework for international growth and peptide collaboration. For more than three decades, Medisca has built its business around the evolving needs of pharmaceutical compounders. That starts with the products it chooses to bring to market but extends much further to the manufa

Wednesday, October 7, 2026

ClaroNav Kolahi Inc. Announces EU MDR Certification for Navient Surgical Navigation System

TORONTO--(BUSINESS WIRE)-- #ENT--ClaroNav Kolahi Inc. (CKI), a global developer and manufacturer of surgical navigation technologies, today announced that its Navient Surgical Navigation System has received certification under the European Union Medical Device Regulation, EU MDR. The certification covers the Navient Image Guided Navigation System and its reusable surgical instruments, allowing CKI to continue offering Navient throughout the European Union under the EU MDR regulatory framework. “EU MDR

Tuesday, October 6, 2026

Nomic’s Proteomics Platform to Power VO Health’s Molecular Fitness Insights

MONTREAL--(BUSINESS WIRE)--Nomic Bio Inc., a proteomics company, and VO Health, a company developing blood-based measures of fitness and functional health, today announced that VO Health is using Nomic’s proteomics platform to develop its Molecular Fitness Blood Test, a new product for measuring VO₂ Max and providing insight into the biology underlying fitness. Built on protein measurements generated by the Nomic Omni 1000 platform, the Molecular Fitness Blood Test is designed for use by athlet

Tuesday, October 6, 2026

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why life sciences requires a biological context layer of its own. ReefIQ™, MindWalk's biological context layer for life sciences, supplies what a horizontal ontology cannot: a governed, model-agnostic representation of what biology does, available from the first day of a de

Tuesday, October 6, 2026

The More Life Company Advancing U.S. Compounded Pharmaceutical Commercialization Pathway for Quicksome™

TORONTO--(BUSINESS WIRE)--The More Life Company Corp. (the “Company” or “MLCO”), (CSE: MLCO) (OTC: TMLCF) is pleased to announce that it has entered into a strategic letter of intent (“LOI”) with an established U.S. 503A compounding pharmacy to advance the development, compounding and commercialization of Quicksome™-enabled prescription compounded pharmaceutical products in the United States. The contemplated relationship is designed to establish dedicated U.S. compounding capability for Quicks

Tuesday, October 6, 2026

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that new clinical and real-world data on ZUNVEYL and acetylcholinesterase inhibitors will be presented at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, taking place October 29-November 1, 2026 and Neuroscience Education I

Tuesday, October 6, 2026

BioRender Unveils the World’s First AI Agent that Builds Images for Scientific Research

TORONTO--(BUSINESS WIRE)--BioRender, the first scientific communication platform to standardize the visual language of biology, today announced the launch of Leo by BioRender, the world’s only AI agent built specifically for scientific figures. Leo is designed to solve an emerging and critical problem: the erosion of trust in science caused by a proliferation of AI-generated images. As AI-generated images proliferate, trust in science erodes AI image generation is advancing at a breakneck pace,

Tuesday, October 6, 2026

Conscience Announces Support for Two Projects Advancing Earlier Diagnosis and Treatment of Childhood Rare Diseases

TORONTO--(BUSINESS WIRE)--Conscience, a Canadian non-profit dedicated to enabling drug discovery through open science and collaboration for the advancement of accessible treatments, is proud to highlight two recently approved projects focused on earlier diagnosis and intervention while advancing the development of therapies for rare diseases in children. The first project is a multi-centre Phase 1/2 clinical trial of a gene therapy for CLN7 Batten disease, a fatal ultra-rare genetic disorder af

Tuesday, October 6, 2026

Give Back Health Innovation Foundation Supports ScarDx to Advance Non-Invasive Kidney Care

TORONTO--(BUSINESS WIRE)--Give Back Health Innovation Foundation (Give Back), a Canadian philanthropic network advancing public health through innovation and technology, today announced its partnership with ScarDx, a newly formed Ontario health technology company developing a non-invasive way to measure kidney scarring, or fibrosis. Through this partnership, Give Back will provide philanthropic capital aligned with its mission and operating model to support the company as it advances its commer

Saturday, October 3, 2026

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by

Friday, October 2, 2026

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 6,000 shares of common stock to a

Thursday, October 1, 2026

SOLVE FSHD Accelerates Development of SFH-4090, a Novel DUX4 Inhibitor for FSHD

VANCOUVER, British Columbia--(BUSINESS WIRE)--SOLVE FSHD today announced new nonclinical data supporting SFH-4090 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The data were presented at the 31st Annual Congress of the World Muscle Society (WMS). SFH-4090, also known as MT-4090, discovered by Tanabe Pharma Corporation (Head Office: Osaka, Japan; Representative Director, CEO: Akihisa Harada), is a chemically novel antisense oligonucleotide (ASO) designed to reduce the expre

Thursday, October 1, 2026

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalan

Wednesday, September 30, 2026

Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape

NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of

Tuesday, September 29, 2026

Closing the Gaps: Canadians Call for More Consistent Breast Cancer Care From Screening Through Survivorship

TORONTO--(BUSINESS WIRE)--Breast Cancer Canada, a national charity dedicated to saving lives through research, today releases new survey data showing public support for a more coordinated approach to breast cancer care, from earlier access to screening and timely diagnosis through personalized treatment and survivorship. Breast cancer is not one disease. It consists of more than 50 distinct types, each with different biological characteristics and personalized treatment considerations. Yet acce

Monday, September 28, 2026

SCIEX Expands BioPhase 8800 System Capabilities to Help Laboratories Accelerate Development and Decision-making for Emerging Therapeutics

MARLBOROUGH, Mass.--(BUSINESS WIRE)--SCIEX, a Danaher company and leader in life science analytical technologies, today announced new capillary electrophoresis (CE) capabilities for the BioPhase 8800 system that help laboratories accelerate development timelines, strengthen compliance, and integrate more seamlessly into automated workflows. Combining enhanced software, automation connectivity, and expanded analytical support for emerging oligonucleotide-based therapeutics, the updates give scie